TARGETING NEW CANCER SOLUTIONS
No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often, this is what happens.
At the core of many oncology therapies are radioisotopes. However, increasingly limited supply inhibits patient outcomes and the development of new therapies.
Innovation
Advancements with radioisotopes
Nusano is combining time-proven technology from universities and world-class research centers with our own breakthrough, patented particle acceleration technology. The result is the first significant advancement in medical radioisotope production in decades – a platform fitting the needs of today and designed for cancer-fighting radiopharmaceuticals of tomorrow.
Inspiration
Life Saving Benefits
Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools.
Implications
a healthy tomorrow
Nusano’s patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
Nusano
Leadership
Nusano is driven by an experienced team of scientists, engineers, and innovators, and guided by leaders with deep expertise in health care, business development and operations.
Chris Lowe
Chief Executive Officer
Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. Read more >>
HOWARD C. LEWIN, MD, FACC, FASNC
CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER
Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>
GLENN B. ROSENTHAL, PH.D.
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER
Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>
Nusano
Board of Directors
Aaron Gerszewski
Managing Director, Wasatch Equity Partners
Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.
Andy Harrison
CEO, Section 32
Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.
Scott Holbrook
GM-CSO, Pharmalogic
Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.
Michael Pellini
Managing Partner, Section 32
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.
Andrew Trister
Chief Scientific Officer, Verily
Dr. Trister leads the Verily’s population health initiatives and provides expertise across the company’s portfolio to further its precision health strategy.
additional directors
company managers
Chris Lowe (CEO) and Howard Lewin (CPDO), also serve on the Board of Directors.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates